Health economic assessment of Trodelvy in advanced triple negative breast cancer

TLV

23 May 2022 - TLV has produced a health economic assessment for the regions for the drug Trodelvy (sacituzumab govitecan). 

The assessment applies to Trodelvy as the sole treatment of adult patients with non-resectable or disseminated, triple negative breast cancer who have previously received two or more systemic treatments, at least one of them for advanced disease.

Read TLV News [Swedish]

Michael Wonder

Posted by:

Michael Wonder